NCT03792815

Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL)

Open-labelled, Multicenter Phase II Clinical Trial of Intravenous Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation in Patients With Poor-risk, Refractory or Relapsed Non-Hodgkin's Lymphoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 51 (actual)
• Sponsor: Soonchunhyang University Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The investigators developed a protocol utilizing once-daily intravenous busulfan/melphalan/etoposide regimen as a conditioning for high-dose therapy (HDT) in the patients with high risk or relapsed Non-Hodgkin's Lymphoma (NHL).

Detailed description

Treatment: busulfan 3.2 mg/kg/day i.v. on day -7, -6, and -5 etoposide 400 mg/m2 i.v. on day -5 and -4 melphalan 50mg/m2/day i.v. on day -3 and -2

Conditions

• Non-Hodgkin's Lymphoma

Interventions

Type	Name	Description
DRUG	Busulfan	busulfan 3.2mg/kg iv on day -8, -7, and -6,
DRUG	Melphalan	melphalan 50mg/m2/day i.v. on day -3 and -2
DRUG	Etoposide	etoposide 400 mg/m2 i.v. on day -5 and -4

Timeline

• Start date: 2009-10-01
• Primary completion: 2011-11-01
• Completion: 2013-09-01
• First posted: 2019-01-03
• Last updated: 2019-01-04

Locations

1 site across 1 country: South Korea